Johanna Ungerstedt
Affiliated to Research | Docent
E-mail: johanna.ungerstedt@ki.se
Visiting address: NEO Medicinaren 25, HERM plan 7, Hälsovägen 7C (lastkaj), 14157 Huddinge/Stockholm
Postal address: H7 Medicin, Huddinge, H7 HERM Ungerstedt, 171 77 Stockholm
Articles
- Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2024;99(1):e13333Rosell A; Karlstrom C; Dahlin JS; Boey D; Klimkowska M; Ax K; Thalin C; Ungerstedt J
- Article: SCIENTIFIC REPORTS. 2023;13(1):21787Kumlin M; Ungerstedt J; Cai H; Leonard E; Fellaender-Tsai L; Qian H
- Journal article: HEMASPHERE. 2023;7(Suppl):e7796003Gotlib J; Castells M; Elberink HO; Siebenhaar F; Hartmann K; Broesby‐Olsen S; George TI; Panse J; Alvarez‐Twose I; Radia D; Tashi T; Livideanu CB; Sabato V; Van Daele P; Cerquozzi S; Dybedal I; Reiter A; Ustun C; Schafhausen P; Bose P; Deangelo DJ; Rein L; Vachhani P; Triggiani M; Rafferty M; Butt N; Oh S; Wortmann F; Ungerstedt J; Taparia M; Kuykendall AT; Yi CA; Mattsson M; Shomali W; Giannetti M; Bidollari I; Lin H; Scherber R; Roche M; Akin C; Maurer M
- Journal article: HEMASPHERE. 2023;7(Suppl):e790629dTesi B; Eriksson A; Baskin B; Lazarevic V; Deneberg S; Höglund M; Fogelstrand L; Ungerstedt J; Pandzic T; Tobiasson M; Garelius HG; Kuchinskaya E; Persson F; Ågerstam H; Uggla B; Hallböök H; Fioretos T; Thuresson A; Lehmann S; Ladenvall C; Barbany G; Vennström L; Ejerblad E; Cavelier L; Cammenga J; Jädersten M; Lindberg EH; Baliakas P
- Article: BLOOD. 2023;142(1):73-89Dolinska M; Cai H; Mansson A; Shen J; Xiao P; Bouderlique T; Li X; Leonard E; Chang M; Gao Y; Medina JP; Kondo M; Sandhow L; Johansson A-SF; Deneberg S; Soederlund S; Jaedersten M; Ungerstedt J; Tobiasson M; Ostman A; Mustjoki S; Stenke L; Le Blanc K; Hellstroem-Lindberg E; Lehmann S; Ekblom M; Olsson-Stroemberg U; Sigvarosson M; Qian H
- Article: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2023;152(1):205-213Soderlund S; Boey D; van Midden W; Kjellander M; Ax K; Qian H; Dahlin JS; Ungerstedt J
- Article: NEJM EVID. 2023;2(6):evidoa2200339Gotlib J; Castells M; Elberink HO; Siebenhaar F; Hartmann K; Broesby-Olsen S; George TI; Panse J; Alvarez-Twose I; Radia DH; Tashi T; Bulai Livideanu C; Sabato V; Heaney M; Van Daele P; Cerquozzi S; Dybedal I; Reiter A; Pongdee T; Barete S; Ustun C; Schwartz L; Ward BR; Schafhausen P; Vadas P; Bose P; Deangelo DJ; Rein L; Vachhani P; Triggiani M; Bonadonna P; Rafferty M; Butt NM; Oh ST; Wortmann F; Ungerstedt J; Guilarte M; Taparia M; Kuykendall AT; Arana Yi C; Ogbogu P; Gaudy-Marqueste C; Mattsson M; Shomali W; Giannetti MP; Bidollari I; Lin H-M; Sulllivan E; Mar B; Scherber R; Roche M; Akin C; Maurer M
- Journal article: LEUKEMIA RESEARCH. 2023;128:107256Kynning MK; Nannya Y; Todisco G; Yoshizato T; Tesi B; Mortera-Blanco T; Bjorklund A-C; Bruck O; Ohyashiki K; Ishikawa T; Ochi Y; Haferlach T; Mustjoki S; Hellstrom-Lindberg E; Ogawa S; Ungerstedt J
- Article: EUROPEAN JOURNAL OF ONCOLOGY NURSING. 2022;60:102172Levedahl KH; Nilsson A; Ungerstedt J; Hedstro M
- Article: LAKARTIDNINGEN. 2022;119:22024Gunnarsson K; Vivar Pomiano N; Tesi B; Tobiasson M; Creignou M; Ungerstedt J
- Article: CANCERS. 2022;14(16):3942Ungerstedt J; Ljung C; Klimkowska M; Gulen T
- Article: BLOOD ADVANCES. 2022;6(15):4439-4449Wu C; Boey D; Bril O; Grootens J; Vijayabaskar MS; Sorini C; Ekoff M; Wilson NK; Ungerstedt JS; Nilsson G; Dahlin JS
- Article: BLOOD. 2022;139(20):3040-3057Cai H; Kondo M; Sandhow L; Xiao P; Johansson A-S; Sasaki T; Zawacka-Pankau J; Tryggvason K; Ungerstedt J; Walfridsson J; Ekblom M; Qian H
- Article: TRANSPLANTATION AND CELLULAR THERAPY. 2021;27(12):991.e1-991.e9Wedge E; Hansen JW; Dybedal I; Creignou M; Ejerblad E; Lorenz F; Werlenius O; Ungerstedt J; Holm MS; Nilsson L; Kittang AO; Antunovic P; Rohon P; Andersen MK; Papaemmanuil E; Bernard E; Jadersten M; Hellstrom-Lindberg E; Gronbaek K; Ljungman P; Friis LS
- Article: LEUKEMIA. 2021;35(8):2371-2381Todisco G; Creignou M; Gall A; Guglielmelli P; Rumi E; Roncador M; Rizzo E; Nannya Y; Pietra D; Elena C; Bono E; Molteni E; Rosti V; Catrical S; Sarchi M; Dimitriou M; Ungerstedt J; Vannucchi AM; Hellstrom-Lindberg E; Ogawa S; Cazzola M; Malcovati L
- Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;192(3):474-483Berggren DM; Kjellander M; Backlund E; Engvall M; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellstrom-Lindberg E; Jadersten M; Ungerstedt J; Ejerblad E
- Article: LANCET HAEMATOLOGY. 2021;8(2):e135-e148Pleyer L; Leisch M; Kourakli A; Padron E; Maciejewski JP; Cirici BX; Kaivers J; Ungerstedt J; Heibl S; Patiou P; Hunter AM; Mora E; Geissler K; Dimou M; Lorenzo M-JJ; Melchardt T; Egle A; Viniou A-N; Patel BJ; Arnan M; Valent P; Roubakis C; Castillo TBD; Galanopoulos A; Munoz MC; Bonadies N; de Almeida AM; Cermak J; Jerez A; Montoro MJ; Cortes A; Pita AA; Andrade BL; Hellstroem-Lindberg E; Germing U; Sekeres MA; List AF; Symeonidis A; Sanz GF; Larcher-Senn J; Greil R
- Article: CANCER RESEARCH. 2020;80(12):2441-2450Ohtani H; Orskov AD; Helbo AS; Gillberg L; Liu M; Zhou W; Ungerstedt J; Hellstrom-Lindberg E; Sun W; Liang G; Jones PA; Gronbaek K
- Article: FRONTIERS IN IMMUNOLOGY. 2020;11:321Salomonsson M; Dahlin JS; Ungerstedt J; Hallgren J
- Article: ALLERGY. 2020;75(2):456-460Salomonsson M; Ungerstedt J; Alvarado-Vazquez PA; Hallgren J
- Article: ALLERGY. 2020;75(1):211-214Grootens J; Ungerstedt JS; Wu C; Levedahl KH; Nilsson G; Dahlin JS
- Journal article: HEMASPHERE. 2019;3(S1):220-221Todisco G; Creignou M; Guglielmelli P; Rumi E; Nannya Y; Galli A; Pietra D; Elena C; Bono E; Dimitriou M; Ungerstedt J; Vannucchi A; Hellström‐Lindberg E; Cazzola M; Ogawa S; Malcovati L
- Journal article: HEMASPHERE. 2019;3(S1):374-375Pleyer L; Leisch M; Kouraklis A; Padron E; Maciejewski JP; Cirici BX; Kaivers J; Ungerstedt J; Sonja H; Peristera P; Hunter A; Mora E; Geissler K; Dimou M; Lorenzo MJJ; Kiesl D; Vyniou A; Patel BJ; Montserrat A; Valent P; Christoforos R; Bernal T; Galanopoulos A; Munoz MC; Bonadies N; Almeida A; Cermak J; Jerez A; Montoro J; Cortés A; Pita AA; Andrade BL; Hellstroem‐Lindberg E; Germing U; Sekeres M; List A; Symeonidis A; Sanz GF; Greil R
- Article: EBIOMEDICINE. 2019;43:150-158Grootens J; Ungerstedt JS; Ekoff M; Ronnberg E; Klimkowska M; Amini R-M; Arock M; Soderlund S; Mattsson M; Nilsson G; Dahlin JS
- Article: FRONTIERS IN ONCOLOGY. 2018;8:407Nair D; Radestad E; Khalkar P; Diaz-Argelich N; Schroder A; Klynning C; Ungerstedt J; Uhlin M; Fernandes AP
- Article: FREE RADICAL BIOLOGY AND MEDICINE. 2018;117:247-257Khalkar P; Ali HA; Codo P; Diaz Argelich N; Martikainen A; Arzenani MK; Lehmann S; Walfridsson J; Ungerstedt J; Fernandes AP
- Article: NEPHRON. 2018;140(4):249-256Serum Glutaredoxin Activity as a Marker of Oxidative Stress in Chronic Kidney Disease: A Pilot StudyLevin A; Nair D; Qureshi AR; Barany P; Heimburger O; Anderstam B; Stenvinkel P; Bruchfeld A; Ungerstedt JS
- Article: BLOOD. 2017;130(16):1785-1794Dahlin JS; Ekoff M; Grootens J; Lof L; Amini R-M; Hagberg H; Ungerstedt JS; Olsson-Stromberg U; Nilsson G
- Article: ONCOTARGET. 2017;8(17):28812-28825Tobiasson M; Abdulkadir H; Lennartsson A; Katayama S; Marabita F; De Paepe A; Karimi M; Krjutskov K; Einarsdottir E; Grovdal M; Jansson M; Ben Azenkoud A; Corddedu L; Lehmann S; Ekwall K; Kere J; Hellstrom-Lindberg E; Ungerstedt J
- Article: ONCOTARGET. 2017;8(6):9647-9659Lyberg K; Ali HA; Grootens J; Kjellander M; Tirfing M; Arock M; Hagglund H; Nilsson G; Ungerstedt J
- Article: ONCOTARGET. 2016;7(16):22103-22115Tobiasson M; McLornan DP; Karimi M; Dimitriou M; Jansson M; Ben Azenkoud A; Jadersten M; Lindberg G; Abdulkadir H; Kulasekararaj A; Ungerstedt J; Lennartsson A; Ekwall K; Mufti GJ; Hellstrom-Lindberg E
- Article: ONCOTARGET. 2016;7(6):6809-6823Agarwal P; Alzrigat M; Parraga AA; Enroth S; Singh U; Ungerstedt J; Osterborg A; Brown PJ; Ma A; Jin J; Nilsson K; Oberg F; Kalushkova A; Jernberg-Wiklund H
- Article: BBA CLINICAL. 2015;4:14-20Glutaredoxin mediated redox effects of coenzyme Q10 treatment in type 1 and type 2 diabetes patientsMontano SJ; Grunler J; Nair D; Tekle M; Fernandes AP; Hua X; Holmgren A; Brismar K; Ungerstedt JS
- Article: ACTA DIABETOLOGICA. 2014;51(2):225-232Du Y; Zhang H; Montano S; Hegestam J; Ekberg NR; Holmgren A; Brismar K; Ungerstedt JS
- Article: FREE RADICAL BIOLOGY AND MEDICINE. 2012;53(11):2002-2007Ungerstedt J; Du Y; Zhang H; Nair D; Holmgren A
- Article: MEDICAL ONCOLOGY. 2012;29(4):2348-2358Nahi H; Remberger M; Machaczka M; Ungerstedt J; Mattson J; Ringden O; Le-Blanc K; Ljungman P; Hagglund H
- Article: MEDICAL ONCOLOGY. 2012;29(3):2191-2199Ungerstedt JS; Watz E; Uttervall K; Johansson B-M; Wahlin BE; Nasman P; Ljungman P; Gruber A; Nygell UA; Nahi H
- Article: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2006;4(10):2164-2169Castaman G; Rodeghiero F; Tosetto A; Cappelletti A; Baudo F; Eikenboom JCJ; Federici AB; Lethagen S; Linari S; Lusher J; Nishino M; Petrini P; Srivastava A; Ungerstedt JS
- Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2006;281(16):10691-10697Hashemy SI; Ungerstedt JS; Avval FZ; Holmgren A
- Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2005;102(3):673-678Ungerstedt JS; Sowa Y; Xu WS; Shao Y; Dokmanovic M; Perez G; Ngo L; Holmgren A; Jiang X; Marks PA
- Article: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2003;1(12):2554-2560Ungerstedt JS; Heimersson K; Söderström T; Hansson M
- Article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2003;131(1):48-52Ungerstedt JS; Blombäck M; Söderström T
- Article: JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY. 2003;15(1):13-18Ungerstedt JS; Grenander Å; Bredbacka S; Blombäck M
- Article: THROMBOSIS RESEARCH. 2003;111(6):329-334Ungerstedt JS; Soop A; Sollevi A; Blombäck M
- Article: SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION. 2002;62(2):135-140Ungerstedt JS; Kallner A; Blombäck M
- Article: INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY. 2001;23(5):313-316Antovic J; Söderström J; Karlman B; Blombäck M
- Show more
All other publications
- Conference publication: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2023;23:S398-S399Gotlib J; Castells M; Elberink HO; Siebenhaar F; Hartmann K; Broesby-Olsen S; George TI; Panse J; Alvarez-Twose I; Radia DH; Tashi T; Livideanu CB; Sabato V; Van Daele P; Cerquozzi S; Dybedal I; Reiter A; Ustun C; Schafhausen P; Bose P; DeAngelo DJ; Rein L; Vachhani P; Triggiani M; Rafferty M; Butt NM; Oh ST; Wortmann F; Ungerstedt J; Taparia M; Kuykendall AT; Yi CA; Mattsson M; Shomali W; Giannetti MP; Bidollari I; Lin H-M; Scherber R; Roche M; Akin C; Maurer M
- Editorial comment: HAEMATOLOGICA. 2023;108(7):1968-1971Landtblom AR; Ungerstedt J; Hedlund A; Tobiasson M; Deneberg S; Jadersten M
- Conference publication: LEUKEMIA RESEARCH. 2023;128:107257Kynning MK; Westerberg E; Forsell L; Creignou M; Berggren DM; Tesi B; Bernard E; Papaemmanuil E; Cavelier L; Valentini D; Hellstrom-Lindberg E; Ejerblad E; Ungerstedt J
- Conference publication: BLOOD. 2022;140:3014Wu C; Boey D; Mo J; Papavasileiou S; Ungerstedt J; Xu M; Nilsson G; Dahlin JS
- Preprint: BIORXIV. 2021Wu C; Boey D; Bril O; Grootens J; Vijayabaskar MS; Sorini C; Ekoff M; Wilson N; Ungerstedt J; Nilsson G; Dahlin J
- Conference publication: BLOOD. 2019;134:844Pleyer L; Leisch M; Kourakli A; Padron E; Maciejewski JP; Xicoy B; Kaivers J; Ungerstedt J; Heibl S; Patiou P; Hunter AM; Mora E; Geissler K; Dimou M; Jimenez M-J; Kiesl D; Viniou N-A; Patel BJ; Sangerman MA; Valent P; Roubakis C; del Castillo TB; Galanopoulos A; Calabuig M; Bonadies N; de Almeida AM; Cermak J; Jerez A; Montoro J; Cortes A; Pita AA; Andrade BL; Lindberg EH; Germing U; Sekeres MA; List AF; Symeonidis A; Sanz GF; Greil R
- Conference publication: CANCER RESEARCH. 2019;79(13):3092Ohtani H; Orskov AD; Helbo AS; Gillberg L; Liu M; Zhou W; Ungerstedt J; Hellstrom-Lindberg E; Sun W; Liang G; Jones PA; Gronbaek K
- Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2018;19(10):E3091-3091Ungerstedt JS
- Review: BLOOD ADVANCES. 2018;2(17):2273-2281Grootens J; Ungerstedt JS; Nilsson G; Dahlin JS
- Preprint: BIORXIV. 2018Grootens J; Ungerstedt JS; Ekoff M; Rönnberg E; Klimkowska M; Amini R-M; Arock M; Söderlund S; Mattsson M; Nilsson G; Dahlin JS
- Meeting abstract: BLOOD. 2016;128(22):1489Dolinska M; Xiao P; Johansson A-S; Sandhow L; Kondo M; Bouderlique T; Ungerstedt J; Hellstrom-Lindberg E; Qian H
- Conference publication: FREE RADICAL BIOLOGY AND MEDICINE. 2016;100:S119-S120Chew E-H; Ng H-L; Kjellander M; Karuppasamy M; Chong AS-Y; Chui W-K; Ungerstedt J
- Letter: LEUKEMIA. 2016;30(9):1953-1956Dahlin JS; Ungerstedt JS; Grootens J; Sander B; Guelen T; Haegglund H; Nilsson G
- Conference publication: HAEMATOLOGICA. 2016;101:70Tobiasson M; Ali HA; Lennartsson A; Katayama S; Marabita F; Karimi M; Khrjutskhov K; Einarsdottir E; Jansson M; Ben Azenkoud A; Ekwall K; Kere J; Hellstrom-Lindberg E; Ungerstedt J
- Conference publication: BLOOD. 2015;126(23):2398Dolinska M; Klang J; Xiao P; Durgaryan A; Sandhow L; Johansson A-S; Kondo M; Deneberg S; Ungerstedt J; Le Blanc K; Stenke L; Ekblom M; Stromberg U; Mustjoki S; Lehmann S; Qian H
- Conference publication: BLOOD. 2015;126(23):2839Tobiasson M; MeLornan D; Karimi M; Dimitriou M; Jansson M; Ben Azenkoud A; Jadersten M; Lindberg G; Abdulkadir H; Kulasekararaj AG; Ungerstedt J; Lennartsson A; Ekwall K; Mufti GJ; Hellstrom-Lindberg E
- Conference publication: BLOOD. 2015;126(23):2834Abdulkadir H; Grootens J; Kjellander M; Lindberg EH; Nilsson G; Ungerstedt J
- Conference publication: HAEMATOLOGICA. 2015;100:776Ungerstedt J; Eriksson A; Olander E; Bergfelt E; Liljeholm M; Kristjanssdottir HL; Erger T; Erixon D; Isaksson C; Birgegard G
- Meeting abstract: LEUKEMIA RESEARCH. 2015;39:S69Abdulkadir H; Tobiasson M; Lennartsson A; Katayama S; Marabita F; Karimi M; Qu Y; Einarsdottir E; Govdal M; Jansson M; Ben Azenkoud A; Lehmann S; Ekwall K; Kere J; Hellstom-Lindberg E; Ungerstedt J
- Conference publication: BLOOD. 2014;124(21):4613Tobiasson M; Karimi M; Dimitriou M; Qu Y; Lennartsson A; Ali HA; Unnikrishnan A; Jadersten M; Jansson M; Ben Azenkoud A; Pimanda JE; Ekwall K; Ungerstedt J; Lehmann S; Hellstrom-Lindberg E
- Conference publication: HAEMATOLOGICA. 2014;99:788Ungerstedt J; Eriksson A; Olander E; Theander J; Liljeholm M; Isaksson C; Birgegard G
- Letter: LEUKEMIA. 2014;28(2):411-413Grovdal M; Karimi M; Tobiasson M; Reinius L; Jansson M; Ekwall K; Ungerstedt J; Kere J; Greco D; Hellstrom-Lindberg E
- Letter: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2004;2(5):838-839Ungerstedt JS; Antovic J; Blombäck M; Bremme K; Johnsson H
- Doctoral thesis: 2003Ungerstedt JS
- Letter: BLOOD. 2002;99(6):2271-2272Ungerstedt JS; Schulman S; Egberg N; Antovic J; Blombäck M
- Show more
Grants
- Deciphering the molecular pathogenesis of chronic myelomonocytic leukemia (CMML)Swedish Cancer Society1 January 2019CMML is a heterogeneous group of patients in terms of symptoms and survival, which varies between 0-120 months. On average, patients live for 12 months. In almost all patients, changes in the genome are found, so-called mutations. The most common is mutation in the TET2 gene. We currently have poor tools for assessing an individual patient's prognosis, and little knowledge of how CMML arises. It is likely that a better understanding of the disease's mechanisms of disease would lead to better tools for prognostic assessment. In about 5% of CMML, bone marrow cancer is also present with systemic mastocytosis. It is unclear how these diseases affect each other. We want to increase knowledge about the mechanisms of CMML disease by studying sorted stem cells and mature cells from CMML patients. We study the genome with advanced sequencing technology, in a large international study with patient samples from around the world. We will identify defects in the genome that can cause CMML disease. We also study a small homogeneous group of CMML patients with TET2 mutation, to find out how different blood cells work differently when they have the TET2 mutation compared to normal cells, and a group with systemic mastocytosis and CMML, where we study if the diseases come from the same origin cell. In the end, our studies will lead to increased knowledge about the mechanisms of origin of CMML and how systemic mastocytosis is associated with and affects CMML disease. It is likely that our molecular findings will help to identify new prognostic markers and also identify molecules that can be attacked with new types of treatments. In the long run, this leads to better opportunities to risk assess an individual patient, as well as opportunities to tailor new individualized treatment according to the molecular patterns we find, in this disease with a poor prognosis, where we do not have any good treatment options at present.
- Systemic mastocytosis emergence mechanisms and identification of new markers for progress and transition in leukemia, as well as a first targeted treatmentSwedish Cancer Society1 January 2018Systemic mastocytosis is an incurable bone marrow cancer. Almost all patients have the same point mutation that causes the disease. Despite this, the patients' symptoms are very different. Most people get a nice course but can have a lot of trouble with allergies and diarrhea, while a small proportion of the patients get a rapidly progressing cancer with death within a couple of years. Some suffer directly from the leukemic form of mastocytosis, and some with a mild process suddenly turn into leukemia. What determines the shape of the individual patient, or why some turn into leukemia, is unknown. There is no disease-inhibiting or curative treatment, only symptom relief. We study different types of molecular markers that will hopefully help us to assess risk and prognosis each individual patient. In previous studies, we have found that drugs that affect the packaging form of DNA selectively kill mutated mast cells while normal cells do not die. We now proceed to understand in depth the mechanism for why the drug only kills tumor cells, in order to partly understand how the packaging form of DNA can be involved in the origin of mastocytosis, but also to understand the mechanism of action to start a clinical trial of the drug at systemic mastocytosis. The goal is to find better diagnostic and prognostic markers in order to be able to identify those patients who are at risk of switching to leukemia and those who have serious forms of mastocytosis, so that we can risk assessing each individual patient. The second goal is to understand the mechanism of action of the drugs that selectively kill mutated mast cells, and then initiate a clinical trial where we include those patients with whom we have identified as high-risk patents with our prognostic markers. By extension, with this first targeted treatment, we hope to stop the disease development and improve prognosis and survival in systemic mastocytosis.
- Systemic mastocytosis emergence mechanisms and identification of new markers for progress and transition in leukemia, as well as a first targeted treatmentSwedish Cancer Society1 January 2017Systemic mastocytosis is an incurable bone marrow cancer. Almost all patients have the same point mutation that causes the disease. Despite this, the patients' symptoms are very different. Most people get a nice course but can have a lot of trouble with allergies and diarrhea, while a small proportion of the patients get a rapidly progressing cancer with death within a couple of years. Some suffer directly from the leukemic form of mastocytosis, and some with a mild process suddenly turn into leukemia. What determines the shape of the individual patient, or why some turn into leukemia, is unknown. There is no disease-inhibiting or curative treatment, only symptom relief. We study different types of molecular markers that will hopefully help us to assess risk and prognosis each individual patient. In previous studies, we have found that drugs that affect the packaging form of DNA selectively kill mutated mast cells while normal cells do not die. We now proceed to understand in depth the mechanism for why the drug only kills tumor cells, in order to partly understand how the packaging form of DNA can be involved in the origin of mastocytosis, but also to understand the mechanism of action to start a clinical trial of the drug at systemic mastocytosis. The goal is to find better diagnostic and prognostic markers in order to be able to identify those patients who are at risk of switching to leukemia and those who have serious forms of mastocytosis, so that we can risk assessing each individual patient. The second goal is to understand the mechanism of action of the drugs that selectively kill mutated mast cells, and then initiate a clinical trial where we include those patients with whom we have identified as high-risk patents with our prognostic markers. By extension, with this first targeted treatment, we hope to stop the disease development and improve prognosis and survival in systemic mastocytosis.
- Systemic mastocytosis emergence mechanisms and identification of new markers for progress and transition in leukemia, as well as a first targeted treatmentSwedish Cancer Society1 January 2016Systemic mastocytosis is an incurable bone marrow cancer. Almost all patients have the same point mutation that causes the disease. Despite this, the patients' symptoms are very different. Most people get a nice course but can have a lot of trouble with allergies and diarrhea, while a small proportion of the patients get a rapidly progressing cancer with death within a couple of years. Some suffer directly from the leukemic form of mastocytosis, and some with a mild process suddenly turn into leukemia. What determines the shape of the individual patient, or why some turn into leukemia, is unknown. There is no disease-inhibiting or curative treatment, only symptom relief. We study different types of molecular markers that will hopefully help us to assess risk and prognosis each individual patient. In previous studies, we have found that drugs that affect the packaging form of DNA selectively kill mutated mast cells while normal cells do not die. We now proceed to understand in depth the mechanism for why the drug only kills tumor cells, in order to partly understand how the packaging form of DNA can be involved in the origin of mastocytosis, but also to understand the mechanism of action to start a clinical trial of the drug at systemic mastocytosis. The goal is to find better diagnostic and prognostic markers in order to be able to identify those patients who are at risk of switching to leukemia and those who have serious forms of mastocytosis, so that we can risk assessing each individual patient. The second goal is to understand the mechanism of action of the drugs that selectively kill mutated mast cells, and then initiate a clinical trial where we include those patients with whom we have identified as high-risk patents with our prognostic markers. By extension, with this first targeted treatment, we hope to stop the disease development and improve prognosis and survival in systemic mastocytosis.
- Swedish Research Council1 January 2013 - 31 December 2015
- Swedish Research Council1 January 2009 - 31 December 2012
Employments
- Affiliated to Research, Department of Medicine, Huddinge, Karolinska Institutet, 2023-2026
Degrees and Education
- Docent, Karolinska Institutet, 2014
- Doctor Of Philosophy, Dept of Surgical Science, Karolinska Institutet, 2003
- University Medical Degree, Karolinska Institutet, 2003